Peter W. Hunt, MD: Gilead Biosciences: Grant/Research Support (Ongoing), Honoraria (Ongoing); Merck Sharp & Dohme Corporation: Advisor/Consultant (Terminated, August 31, 2023), donated drug for NIH-sponsored clinical trial (Terminated, August 31, 2023); Viiv Healthcare: Advisor/Consultant (Terminated, March 30, 2023), Honoraria (Terminated, March 30, 2023)
